{"groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"FG000","title":"Bevacizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: wrong cell type"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: wrong primary"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: improper prior treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients must have persistent or recurrent squamous cell carcinoma of the cervix with documented disease progression. Patients were required to have measurable disease at time of study entry. They were required to have had a prior cytotoxic regimen.","recruitmentDetails":"The study was activated on 4/29/2002 and closed to accrual on 11/6/2006 (suspended from 2/7/2005 to 10/30/2005)."}